The company is gene editing crops to make our food supply more resilient to climate change.

This makes the organs virus-free and less likely to trigger an immune response, improving their safety and durability.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial ...

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Algen Biotechnologies said on Monday it had agreed to grant AstraZeneca a license to develop therapies the U.S.-based biotech ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

Some conservation groups are calling for an effective ban on genetic modification, but others say these technologies are ...

Under the deal, AstraZeneca will get exclusive rights to develop therapies that target immune system-related disorders. The ...

If you have $200, you could invest in one of each: a well-established pharma company with a track record of billion-dollar ...